EXSCIENTIA
8.7.2021 10:02:52 CEST | Business Wire | Press release
Exscientia has received a grant from the Bill & Melinda Gates Foundation and Gates Philanthropy Partners, as part of the COVID-19 Therapeutics Accelerator. This is to expedite the optimisation of a new class of COVID-19 therapeutics created using its artificial intelligence (AI) drug design platform. Exscientia has demonstrated proof-of-concept by using its AI platform to design a novel class of inhibitors targeting the SARS-CoV-2’s main protease enzyme, Mpro , also known as 3CLpro , the causative agent of COVID-19. Mpro is essential for the replication of coronavirus, so administering an Mpro inhibitor to patients as a standalone antiviral or alongside other concurrent treatments could provide a useful frontline therapy.
Exscientia’s AI-based platform will be used to optimise the novel small molecule inhibitors into a therapeutic development candidate, designed to be active against SARS-CoV-2 and other coronaviruses. The project’s goal is to identify potential pan-coronavirus therapeutics that could be effective against COVID-19, and also new mutations or other SARS viruses that may emerge.
The new grant provided by the COVID-19 Therapeutics Accelerator - an initiative launched by the Gates Foundation, Wellcome, and Mastercard to speed up the response to the pandemic - comes in addition to recent backing from the Gates Foundation supporting Exscientia’s work in developing treatments for tuberculosis, malaria and non-hormonal contraceptives which began in January 2021. Under the new grant, Exscientia will receive $1.5 million which will be used to advance a development candidate on achieving defined milestones. The virus protease inhibitors will be designed using Exscientia’s AI-driven drug discovery platform, which delivers optimised compounds, fulfilling complex design goals faster and more effectively than with conventional drug discovery methods.
Dr. Denise Barrault, Senior Portfolio Manager at Exscientia, commented, “The danger of new emerging strains and mutations of coronavirus means there is an urgent need for new antiviral drugs in this pandemic alongside vaccines, to respond more quickly in potential future coronavirus pandemics. We believe that the world needs innovation to accelerate the discovery of more effective counter-measures for a range of infectious diseases, including COVID-19.”
Exscientia has built a track record of improving and accelerating drug discovery by advancing the first three completely AI-designed small molecule drug candidates into clinical trials. In addition to its own proprietary programmes, Exscientia has entered into collaborations with major pharmaceutical companies including Bristol Myers Squibb, Bayer, Sanofi and Dainippon Sumitomo, as well as multiple biotech companies. The company currently has more than 20 partners or wholly owned programmes for diseases involving cancer, immunology, the central nervous system, and genetic mutations.
ENDS
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering and designing the best possible medicines in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drugs are created. Exscientia’s AI platform has now designed three drugs that are in Phase 1 human clinical trials.
Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia’s AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.
Exscientia has offices in Oxford, Miami, Osaka and Dundee. For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210708005344/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Delivers Fourth Quantum Computer in Finland, Operational at Aalto University11.3.2026 11:32:00 CET | Press release
This is the fourth quantum computer deployed by IQM to customers in Finland to boost research and education in a growing ecosystem. The system named Aalto Q20 quantum computer is online at Aalto University and will enable students and scientists a unique first-hand access to a world-class quantum computer. The university will use the quantum computer to perform scientific experiments on advanced level and to support national and European quantum research activities. IQM Quantum Computers, the global leader in deployed on-premises, full-stack superconducting quantum computers, today announced the launch of Aalto Q20 quantum computer in Finland, reinforcing its commercial leadership in the quantum industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311215316/en/ Ribbon cutting of the Aalto Q20 quantum computer delivered by IQM. The 20-qubit system, which is operational at Aalto University, is the fourth quantum compute
Chiesi and Bespak Partner to Advance Carbon Minimal Inhaler Production With UK Manufacturing Site11.3.2026 11:00:00 CET | Press release
Highlights Agreement builds on existing Chiesi-Bespak collaboration, reinforcing a trusted relationship as Chiesi works to evolve a portfolio of extrafine formulation Carbon Minimal Inhalers1, ensuring patients retain continuity of care while reducing carbon emissionsBespak’s leadership in low-GWP propellant inhaler manufacturing along with significant expansion at its Holmes Chapel site strengthens Chiesi’s global supply chain resiliencePartnership aligns with the science-based climate commitments of both companies Chiesi Group ("Chiesi"), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, today announced an expansion of their long-standing partnership, increasing pressurized metered dose inhaler (pMDI) manufacturing capacity at Bespak’s Holmes Chapel site to support the next phase of Chiesi’s Carbon Minimal Inhaler (CMI) program. This press release features multi
NTT DATA Unveils NVIDIA-Powered Enterprise AI Factories to Support Secure AI Adoption and Help Clients Drive Measurable ROI11.3.2026 11:00:00 CET | Press release
NTT DATA drives success in healthcare, manufacturing and other sectors with NVIDIA-powered technologies NTT DATA AI solutions now integrate NVIDIA AI Enterprise software, including NVIDIA NeMo and NIM Microservices to create a full-stack, production-ready, GPU-accelerated agentic AI platform NTT DATA, a global leader in AI, digital business and technology services, announced an initiative to deliver NVIDIA-powered enterprise AI factories that drive innovation and operational excellence for organizations worldwide. NTT DATA’s new enterprise AI factories provide full-stack, domain-specific solutions that integrate data, infrastructure, workflows and governance to give organizations a repeatable and production-ready operating model for enterprise AI. NTT DATA enterprise AI factories, powered by NVIDIA, are adaptive, intelligent and automated ecosystems designed to help clients accelerate return on investment by scaling enterprise AI efficiently and managing the full AI lifecycle end to en
Haleon Strengthens Commitment to China as Consumers Focus on Better Everyday Health11.3.2026 10:00:00 CET | Press release
£65m investment in new oral health manufacturing plant in Shanghai to support growth in the world’s largest gum health market Haleon aiming to extend gum health brand parodontax to 30 Chinese cities by end of 2027 - including its fastest growing cities – reaching aspirational shoppers in-store and online Custom designed taste, foamier sensation and premium packaging to appeal to local consumers Haleon, a consumer company that is solely focused on better everyday health, is investing £65 million in a new state-of-the-art oral health manufacturing site in Shanghai. The facility will support the expansion of its oral care portfolio – which includes the global brands Sensodyne and parodontax – into China’s fast-growing tier 2 and tier 3 cities, where rising incomes, growing awareness of everyday health and a shift towards trusted, branded products are reshaping consumer behaviour. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202
Eurofins Biomnis Launches New Clinical LC‑MS/MS Method for the Detection of Cereulide Toxin in Stool Samples11.3.2026 09:00:00 CET | Press release
Eurofins Biomnis, a leading European provider of specialised clinical diagnostics services, and part of the global network of Eurofins laboratories, announces the successful development and validation of a new liquid chromatography tandem mass spectrometry (LC‑MS/MS) method for the detection and quantification of cereulide toxin in human stool samples. This innovation underlines Eurofins Biomnis’ diagnostic innovation, and its commitment to contributing its expertise to reducing diagnostic uncertainty with solutions that support clinicians and laboratories nationwide and internationally. Eurofins Biomnis has fully validated the method for human stool samples, taking into account matrix effects and meeting the requirements of ISO 15189 (with the exception of inter‑method comparison on pathological clinical samples). Cereulide, a toxin produced by specific strains of Bacillus cereus, has recently raised significant public attention following contamination events involving infant formula
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom